BackVertex Pharmaceuticals Overview
Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($600) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$538.6

Average Target Price

$596.5310.8% upside

15 analysts in the last 4 months

High: $665 | Low: $442

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-03Cantor FitzgeraldCarter Gould$61914.9% upsideOpen
2026-11-03Wells FargoMohit Bansal$65020.7% upsideOpen
2026-10-08RBC Capital$5766.9% upsideOpen
2026-09-28UBS$61514.2% upsideOpen
2026-09-23JefferiesAkash Tewari$64018.8% upsideOpen
2026-09-22H.C. WainwrightAndrew Fein$64119% upsideOpen
2026-09-01Morgan StanleyTerence Flynn$66523.5% upsideOpen
2026-09-01Goldman Sachs$65321.2% upsideOpen
2026-08-11BernsteinJeffrey Walch$60812.9% upsideOpen
2026-08-10Wolfe ResearchAndy Chen$5624.3% upsideOpen
2026-08-05Truist Financial$5654.9% upsideOpen
2026-08-05Barclays$61714.6% upsideOpen
2026-08-04Canaccord Genuity$44217.9% downsideOpen
2026-08-04Cantor Fitzgerald$59510.5% upsideOpen
2026-08-04Stifel Nicolaus$5007.2% downsideOpen
2026-07-13Truist Financial$5604% upsideOpen
2026-07-13UBS$5858.6% upsideOpen
2026-07-07RBC Capital$5705.8% upsideOpen
2026-07-07Robert W. Baird$35035% downsideOpen
2026-05-27Truist FinancialDanielle Brill$5420.6% upsideOpen
2026-05-06Barclays$61514.2% upsideOpen
2026-05-05Bernstein$5726.2% upsideOpen
2026-05-05RBC CapitalBrian Abrahams$5430.8% upsideOpen
2026-05-05Canaccord Genuity$43619% downsideOpen
2026-05-05Morgan Stanley$61614.4% upsideOpen
2026-04-30Canaccord Genuity$43718.9% downsideOpen
2026-04-10Morgan Stanley$61213.6% upsideOpen
2026-03-10Truist FinancialJoon Lee$5252.5% downsideOpen
2026-03-10JefferiesAkash Tewari$5807.7% upsideOpen
2026-03-02BMO CapitalEvan David Seigerman$60011.4% upsideOpen
2026-02-17Canaccord Genuity$44118.1% downsideOpen
2026-02-17H.C. WainwrightAndrew Fein$5919.7% upsideOpen
2026-02-17BarclaysEliana Merle$60712.7% upsideOpen
2026-02-13ScotiabankLouise Chen$5583.6% upsideOpen
2026-02-13Morgan StanleyTerence Flynn$5705.8% upsideOpen
2026-02-13H.C. WainwrightAndrew Fein$5183.8% downsideOpen
2026-02-13Stifel NicolausPaul Matteis$46613.5% downsideOpen
2026-02-13Cantor Fitzgerald$5909.5% upsideOpen
2026-02-13Bernstein$5777.1% upsideOpen
2026-02-13RBC Capital$5410.4% upsideOpen
2026-01-27Barclays$60612.5% upsideOpen
2026-01-26UBS$5451.2% upsideOpen
2026-01-23Evercore ISICory Kasimov$5301.6% downsideOpen
2026-01-22RBC CapitalBrian Abrahams$5461.4% upsideOpen
2026-01-06UBSMichael Yee$5350.7% downsideOpen
2025-12-29Leerink Partners$5252.5% downsideOpen
2025-12-05Morgan Stanley$5644.7% upsideOpen
2025-12-03Morgan StanleyTerence Flynn$5164.2% downsideOpen
2025-11-04Cantor FitzgeraldCarter Gould$48510% downsideOpen
2025-11-04RBC Capital$41522.9% downsideOpen

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals posts a target price of $600. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $600 for VRTX means covering analysts, on average, see the stock 10.8% upside of $538.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for VRTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vertex Pharmaceuticals's other metric pages and overview cover the third.

Judging Vertex Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $600 here, then scan peer and history charts to see if the gap is persistent.